Congestive heart failure (CHF) afflicts more than 4.6 million people in the United States and increases at a rate of 400,000 newly diagnosed patients per year.
With more than 1.5 million hospital admissions per year attributed to CHF, it is the number one cause of hospitalization.
Hospital length of stay (LOS) is one key determinant of greater hospital costs and has been the focus in some economic studies of CHF patients.
In the present study, the potential economic benefits for hospitals from the implementation of improved disease-specific management programs in the treatment of CHF have been quantified in terms of LOS.
We estimated the potential effects of disease management on LOS as a residual variation across hospitals, controlling for the effects of patient-specific characteristics, including severity of disease, health status, insurance status, and comorbidities.
The study entry criteria and random sample selection yielded 5242 records for analysis.
The average LOS was 7.1 days.
The fixed effects or disease management practices across hospitals contribute to the explanatory power of the model by 4%. The 104 hospital-specific fixed effects measuring the potential impact of the differences in disease management relative to the reference hospital had values ranging from - 3.41 to 4.33 days, for a total spread of 7.74 days, even after controlling for all other factors. (...)
Mots-clés Pascal : Insuffisance cardiaque, Hospitalisation, Temps séjour, Traitement, Choix, Chimiothérapie, Diminution coût, Hôpital, Homme, Economie santé, Appareil circulatoire pathologie, Cardiopathie
Mots-clés Pascal anglais : Heart failure, Hospitalization, Residence time, Treatment, Choice, Chemotherapy, Cost lowering, Hospital, Human, Health economy, Cardiovascular disease, Heart disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 96-0442127
Code Inist : 002B02F09. Création : 10/04/1997.